Vigorous exercise may prevent progression of low-risk prostate cancer

The idea that exercise and physicial fitness may be associated with a reduction in risk of disease progression in men with relatively low-risk prostate cancer is hardly new, but

Dutasteride as a single agent for low-risk prostate cancer

According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®).

Who needs aggressive treatment after initial radiation … and who does not?

A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality.

U.S. FDA approves NADiA ProsVue prognostic test for prostate cancer

According to a media release issued on Thursday by IRIS International, the U.S. Food & Drug Administration (FDA) has approved the company’s NADiA® ProsVue™ test as a prognostic marker that can “aid in identifying” men at reduced risk for recurrence of prostate cancer in the first 8 years after a prostatectomy.

Manserin as possible marker of prostate cancer progression

“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer.

The proposed REALITY trial and the impact of statins on prostate cancer

As a mentioned earlier this week, a new article by Moyad and Klotz has suggested that it may be possible to carry out a randomized clinical trial to evaluate the impact of statin therapy on the progression of early stage prostate cancer.

Risk associated with rapid rise in PSA immediately following HIFU

An article in the April issue of Clinical Medical Insights: Oncology suggests that a rapid post-treatment increase in the PSA levels of men treated for localized prostate cancer with high-intensity focused ultrasound (HIFU) may indicate later risk for biochemical recurrence.

Diet, veggies, MEAL, and prostate cancer progression

The issue of whether changes in diet and the use of supplements affect risk for and progression of prostate cancer is regular fodder for media coverage. One of the major problems is that there has never been a large, well-controlled clinical trial that could provide definitive (“level 1″) evidence in support of the clinical benefit [...]

Testosterone therapy in untreated men with prostate cancer

One of the most controversial issues in the management of prostate cancer is whether testosterone therapy can be given to men who have or are at risk for the recurrence of this type of cancer. Such use of testosterone therapy has been contraindicated for many years, but recent data has started to question this longstanding [...]

Another update on statins in prostate cancer

Out of the 600+ presentations at the IMPaCT meeting in Orlando last week, your correspondent somehow managed to overlook an interesting poster that offers new evidence in support of the potential benefit of statin therapy in the prevention and management of prostate cancer.

Does ProsVue accurately identify men at minimal risk for disease progression?

The NADiA® ProsVue™ test is a highly sensitive investigational PSA immunoassay.

It’s time to invest in pomegranate stocks (or orchards)!

It appears that regular use of commercially available pomegranate extract really does have a significant impact on PSA doubling time (PSADT) among men with a rising PSA but no indication of bone metastasis.

5-ARIs, active surveillance, and prostate cancer progression

We will presumably be at least a little wiser about this issue when data from the REDEEM trial are presented at the Genitourinary Cancers Symposium in Orlando on Thursday; however, data from Canada already suggest that 5α-reductase inhibitors (5-ARIs) affect progression of low-risk forms of prostate cancer.

Salvage cryotherapy as second-line treatment after first-line radiation therapy

We really have no idea what the “best” way is to treat men with progressive disease after first-line radiation therapy.

Perhaps all too much FUS about something …

As usual, some of our friends in the media are over-hyping a recent publication about the possible effects of a protein called FUS/TLS in the progression of prostate cancer.

Follow

Get every new post delivered to your Inbox.

Join 269 other followers